Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 385

1.

The Glycosylation Site of Myelin Oligodendrocyte Glycoprotein Affects Autoantibody Recognition in a Large Proportion of Patients.

Marti Fernandez I, Macrini C, Krumbholz M, Hensbergen PJ, Hipgrave Ederveen AL, Winklmeier S, Vural A, Kurne A, Jenne D, Kamp F, Gerdes LA, Hohlfeld R, Wuhrer M, Kümpfel T, Meinl E.

Front Immunol. 2019 Jun 11;10:1189. doi: 10.3389/fimmu.2019.01189. eCollection 2019.

2.

Immune checkpoint blockade for treating progressive multifocal leukoencephalopathy.

Hohlfeld R.

Lancet Neurol. 2019 Jul;18(7):623-624. doi: 10.1016/S1474-4422(19)30183-8. Epub 2019 May 16. No abstract available.

PMID:
31104991
3.

DNA methylation signatures of monozygotic twins clinically discordant for multiple sclerosis.

Souren NY, Gerdes LA, Lutsik P, Gasparoni G, Beltrán E, Salhab A, Kümpfel T, Weichenhan D, Plass C, Hohlfeld R, Walter J.

Nat Commun. 2019 May 7;10(1):2094. doi: 10.1038/s41467-019-09984-3.

4.

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.

Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, Wiendl H.

Ther Adv Neurol Disord. 2019 Apr 1;12:1756286419836571. doi: 10.1177/1756286419836571. eCollection 2019. Review.

5.

Immune dysbalance in childhood multiple sclerosis: a 'chicken or the egg' conundrum.

Hohlfeld R.

Brain. 2019 Mar 1;142(3):490-492. doi: 10.1093/brain/awz008. No abstract available.

PMID:
30810210
6.

Abundant glutamic acid decarboxylase (GAD)-reactive B cells in gad-antibody-associated neurological disorders.

Thaler FS, Thaller AL, Biljecki M, Schuh E, Winklmeier S, Mahler CF, Gerhards R, Völk S, Schnorfeil F, Subklewe M, Hohlfeld R, Kümpfel T, Meinl E.

Ann Neurol. 2019 Mar;85(3):448-454. doi: 10.1002/ana.25414. Epub 2019 Jan 28.

PMID:
30635933
7.

Managing Risks with Immune Therapies in Multiple Sclerosis.

Förster M, Küry P, Aktas O, Warnke C, Havla J, Hohlfeld R, Mares J, Hartung HP, Kremer D.

Drug Saf. 2019 May;42(5):633-647. doi: 10.1007/s40264-018-0782-8. Review.

PMID:
30607830
8.

Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein.

Spadaro M, Winklmeier S, Beltrán E, Macrini C, Höftberger R, Schuh E, Thaler FS, Gerdes LA, Laurent S, Gerhards R, Brändle S, Dornmair K, Breithaupt C, Krumbholz M, Moser M, Krishnamoorthy G, Kamp F, Jenne D, Hohlfeld R, Kümpfel T, Lassmann H, Kawakami N, Meinl E.

Ann Neurol. 2018 Aug;84(2):315-328. doi: 10.1002/ana.25291. Epub 2018 Sep 9.

PMID:
30014603
9.

Crosstalk between Akt signaling and cold shock proteins in mediating invasive cell phenotypes.

Hohlfeld R, Brandt S, Bernhardt A, Gorny X, Schindele D, Jandrig B, Schostak M, Isermann B, Lindquist JA, Mertens PR.

Oncotarget. 2018 Apr 10;9(27):19039-19049. doi: 10.18632/oncotarget.24886. eCollection 2018 Apr 10.

10.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2019 Apr;25(5):661-668. doi: 10.1177/1352458518763541. Epub 2018 Mar 13.

PMID:
29532745
11.

Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.

Yshii LM, Hohlfeld R, Liblau RS.

Nat Rev Neurol. 2017 Dec;13(12):755-763. doi: 10.1038/nrneurol.2017.144. Epub 2017 Nov 6. Review.

PMID:
29104289
12.

Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.

Meinl I, Havla J, Hohlfeld R, Kümpfel T.

Mult Scler. 2018 Jun;24(7):991-994. doi: 10.1177/1352458517731913. Epub 2017 Sep 18.

PMID:
28920764
13.

Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice.

Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z, Liu C, Klotz L, Stauffer U, Baranzini SE, Kümpfel T, Hohlfeld R, Krishnamoorthy G, Wekerle H.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10719-10724. doi: 10.1073/pnas.1711233114. Epub 2017 Sep 11.

14.

B-cells as therapeutic targets in neuro-inflammatory diseases.

Hohlfeld R.

Clin Immunol. 2018 Jan;186:51-53. doi: 10.1016/j.clim.2017.07.013. Epub 2017 Jul 21.

PMID:
28736276
15.

Visualizing context-dependent calcium signaling in encephalitogenic T cells in vivo by two-photon microscopy.

Kyratsous NI, Bauer IJ, Zhang G, Pesic M, Bartholomäus I, Mues M, Fang P, Wörner M, Everts S, Ellwart JW, Watt JM, Potter BVL, Hohlfeld R, Wekerle H, Kawakami N.

Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):E6381-E6389. doi: 10.1073/pnas.1701806114. Epub 2017 Jul 17.

16.

Stop inflammation and you stop neurodegeneration in MS - Commentary.

Hohlfeld R.

Mult Scler. 2017 Sep;23(10):1323-1324. doi: 10.1177/1352458517707587. Epub 2017 May 2. No abstract available.

PMID:
28463074
17.

T Cell-Transfer Experimental Autoimmune Encephalomyelitis: Pillar of Multiple Sclerosis and Autoimmunity.

Hohlfeld R, Steinman L.

J Immunol. 2017 May 1;198(9):3381-3383. doi: 10.4049/jimmunol.1700346. No abstract available.

18.

Ocrelizumab in multiple sclerosis: markers and mechanisms.

Hohlfeld R, Meinl E.

Lancet Neurol. 2017 Apr;16(4):259-261. doi: 10.1016/S1474-4422(17)30048-0. No abstract available.

PMID:
28327329
19.

Patient-to-patient transmission of natalizumab-associated PML?

Hohlfeld R, Havla J, Kümpfel T.

Mult Scler. 2017 Oct;23(11):1564-1565. doi: 10.1177/1352458517701316. Epub 2017 Mar 20. No abstract available.

PMID:
28318370
20.

Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement.

Schuh E, Musumeci A, Thaler FS, Laurent S, Ellwart JW, Hohlfeld R, Krug A, Meinl E.

J Immunol. 2017 Apr 15;198(8):3081-3088. doi: 10.4049/jimmunol.1601746. Epub 2017 Mar 10.

21.

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Havla J, Warnke C, Derfuss T, Kappos L, Hartung HP, Hohlfeld R.

Dtsch Arztebl Int. 2016 Dec 26;113(51-52):879-886. doi: 10.3238/arztebl.2016.0879. Review.

22.

Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.

Havla J, Kümpfel T, Schinner R, Spadaro M, Schuh E, Meinl E, Hohlfeld R, Outteryck O.

J Neurol. 2017 Jan;264(1):139-151. doi: 10.1007/s00415-016-8333-7. Epub 2016 Nov 14.

PMID:
27844165
23.

Antiglutamatergic therapy for multiple sclerosis?

Hohlfeld R, Kerschensteiner M.

Lancet Neurol. 2016 Sep;15(10):1003-4. doi: 10.1016/S1474-4422(16)30163-6. Epub 2016 Aug 8. No abstract available.

PMID:
27571145
24.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Suggests Normal Perfusion in Normal-Appearing White Matter in Multiple Sclerosis.

Ingrisch M, Sourbron S, Herberich S, Schneider MJ, Kümpfel T, Hohlfeld R, Reiser MF, Ertl-Wagner B.

Invest Radiol. 2017 Mar;52(3):135-141. doi: 10.1097/RLI.0000000000000320.

PMID:
27548346
25.

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis.

Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E, Metz I, Blaschek A, Dick A, Brück W, Hohlfeld R, Meinl E, Kümpfel T.

Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257. doi: 10.1212/NXI.0000000000000257. eCollection 2016 Oct.

26.

Features of Human CD3+CD20+ T Cells.

Schuh E, Berer K, Mulazzani M, Feil K, Meinl I, Lahm H, Krane M, Lange R, Pfannes K, Subklewe M, Gürkov R, Bradl M, Hohlfeld R, Kümpfel T, Meinl E, Krumbholz M.

J Immunol. 2016 Aug 15;197(4):1111-7. doi: 10.4049/jimmunol.1600089. Epub 2016 Jul 13.

27.

CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis.

Gerdes LA, Held K, Beltrán E, Berking C, Prinz JC, Junker A, Tietze JK, Ertl-Wagner B, Straube A, Kümpfel T, Dornmair K, Hohlfeld R.

Ann Neurol. 2016 Aug;80(2):294-300. doi: 10.1002/ana.24715. Epub 2016 Jul 15.

28.

Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins.

Brändle SM, Obermeier B, Senel M, Bruder J, Mentele R, Khademi M, Olsson T, Tumani H, Kristoferitsch W, Lottspeich F, Wekerle H, Hohlfeld R, Dornmair K.

Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7864-9. doi: 10.1073/pnas.1522730113. Epub 2016 Jun 20.

29.

Multiple sclerosis: Molecular mimicry of an antimyelin HLA class I restricted T-cell receptor.

Rühl G, Niedl AG, Patronov A, Siewert K, Pinkert S, Kalemanov M, Friese MA, Attfield KE, Antes I, Hohlfeld R, Dornmair K.

Neurol Neuroimmunol Neuroinflamm. 2016 May 17;3(4):e241. doi: 10.1212/NXI.0000000000000241. eCollection 2016 Aug.

30.

Cytotoxic T cells go awry in inclusion body myositis.

Hohlfeld R, Schulze-Koops H.

Brain. 2016 May;139(Pt 5):1312-4. doi: 10.1093/brain/aww053. No abstract available.

PMID:
27189577
31.

Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.

Gross CC, Schulte-Mecklenbeck A, Rünzi A, Kuhlmann T, Posevitz-Fejfár A, Schwab N, Schneider-Hohendorf T, Herich S, Held K, Konjević M, Hartwig M, Dornmair K, Hohlfeld R, Ziemssen T, Klotz L, Meuth SG, Wiendl H.

Proc Natl Acad Sci U S A. 2016 May 24;113(21):E2973-82. doi: 10.1073/pnas.1524924113. Epub 2016 May 9.

32.

Mitochondrial DNA Variation and Heteroplasmy in Monozygotic Twins Clinically Discordant for Multiple Sclerosis.

Souren NY, Gerdes LA, Kümpfel T, Lutsik P, Klopstock T, Hohlfeld R, Walter J.

Hum Mutat. 2016 Aug;37(8):765-75. doi: 10.1002/humu.23003. Epub 2016 May 13.

PMID:
27119776
33.

Alemtuzumab and Multiple Sclerosis: Another Note of Caution.

Hohlfeld R, Kümpfel T.

JAMA Neurol. 2016 Jun 1;73(6):637-8. doi: 10.1001/jamaneurol.2016.0259. No abstract available.

PMID:
27042804
34.

Guidelines on dermatomyositis--excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology.

Sunderkötter C, Nast A, Worm M, Dengler R, Dörner T, Ganter H, Hohlfeld R, Melms A, Melzer N, Rösler K, Schmidt J, Sinnreich M, Walter MC, Wanschitz J, Wiendl H.

J Dtsch Dermatol Ges. 2016 Mar;14(3):321-38. doi: 10.1111/ddg.12909.

PMID:
26972210
35.

[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H.

Nervenarzt. 2016 Jun;87(6):645-59. doi: 10.1007/s00115-016-0077-1. Review. German.

PMID:
26927677
36.

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, Melms A, Tackenberg B, Schalke B, Schneider-Gold C, Zimprich F, Meuth SG, Wiendl H.

J Neurol. 2016 Aug;263(8):1473-94. doi: 10.1007/s00415-016-8045-z. Epub 2016 Feb 17. Review.

37.

The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets.

Hohlfeld R, Dornmair K, Meinl E, Wekerle H.

Lancet Neurol. 2016 Feb;15(2):198-209. doi: 10.1016/S1474-4422(15)00334-8. Epub 2015 Dec 24. Review.

PMID:
26724103
38.

The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research.

Hohlfeld R, Dornmair K, Meinl E, Wekerle H.

Lancet Neurol. 2016 Mar;15(3):317-31. doi: 10.1016/S1474-4422(15)00313-0. Epub 2015 Dec 24. Review. Erratum in: Lancet Neurol. 2016 Mar;15(3):241.

PMID:
26724102
39.

Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid.

Wuhrer M, Selman MH, McDonnell LA, Kümpfel T, Derfuss T, Khademi M, Olsson T, Hohlfeld R, Meinl E, Krumbholz M.

J Neuroinflammation. 2015 Dec 18;12:235. doi: 10.1186/s12974-015-0450-1.

40.

PML risk stratification using anti-JCV antibody index and L-selectin.

Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H.

Mult Scler. 2016 Jul;22(8):1048-60. doi: 10.1177/1352458515607651. Epub 2015 Oct 2.

PMID:
26432858
41.

Fingolimod induces neuroprotective factors in human astrocytes.

Hoffmann FS, Hofereiter J, Rübsamen H, Melms J, Schwarz S, Faber H, Weber P, Pütz B, Loleit V, Weber F, Hohlfeld R, Meinl E, Krumbholz M.

J Neuroinflammation. 2015 Sep 30;12:184. doi: 10.1186/s12974-015-0393-6.

42.

T-cell receptor repertoire of human peripheral CD161hiTRAV1-2+ MAIT cells revealed by next generation sequencing and single cell analysis.

Held K, Beltrán E, Moser M, Hohlfeld R, Dornmair K.

Hum Immunol. 2015 Sep;76(9):607-14. doi: 10.1016/j.humimm.2015.09.002. Epub 2015 Sep 14.

PMID:
26382249
43.

[Current aspects of therapy conversion for multiple sclerosis].

Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, Brück W, Limmroth V, Haghikia A, Hartung HP, Stangel M, Hohlfeld R, Hemmer B, Gold R, Wiendl H, Zipp F.

Nervenarzt. 2015 Oct;86(10):1236-47. doi: 10.1007/s00115-015-4368-8. Review. German.

PMID:
26269289
44.

[Multiple sclerosis and microbiota. From genome to metagenome?].

Hohlfeld R, Wekerle H.

Nervenarzt. 2015 Aug;86(8):925-33. doi: 10.1007/s00115-014-4248-7. German.

PMID:
26099498
45.

γ-Secretase directly sheds the survival receptor BCMA from plasma cells.

Laurent SA, Hoffmann FS, Kuhn PH, Cheng Q, Chu Y, Schmidt-Supprian M, Hauck SM, Schuh E, Krumbholz M, Rübsamen H, Wanngren J, Khademi M, Olsson T, Alexander T, Hiepe F, Pfister HW, Weber F, Jenne D, Wekerle H, Hohlfeld R, Lichtenthaler SF, Meinl E.

Nat Commun. 2015 Jun 11;6:7333. doi: 10.1038/ncomms8333.

46.

Expanding spectrum of neurologic manifestations in patients with NLRP3 low-penetrance mutations.

Schuh E, Lohse P, Ertl-Wagner B, Witt M, Krumbholz M, Frankenberger M, Gerdes LA, Hohlfeld R, Kümpfel T.

Neurol Neuroimmunol Neuroinflamm. 2015 May 14;2(4):e109. doi: 10.1212/NXI.0000000000000109. eCollection 2015 Aug.

47.

αβ T-cell receptors from multiple sclerosis brain lesions show MAIT cell-related features.

Held K, Bhonsle-Deeng L, Siewert K, Sato W, Beltrán E, Schmidt S, Rühl G, Ng JK, Engerer P, Moser M, Klinkert WE, Babbe H, Misgeld T, Wekerle H, Laplaud DA, Hohlfeld R, Dornmair K.

Neurol Neuroimmunol Neuroinflamm. 2015 May 7;2(4):e107. doi: 10.1212/NXI.0000000000000107. eCollection 2015 Aug.

48.

Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study.

Kremenchutzky M, O'Connor P, Hohlfeld R, Zhang-Auberson L, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Kappos L.

Mult Scler Relat Disord. 2014 May;3(3):341-9. doi: 10.1016/j.msard.2013.10.006. Epub 2013 Nov 5.

49.

Histopathology and clinical course of MOG-antibody-associated encephalomyelitis.

Spadaro M, Gerdes LA, Mayer MC, Ertl-Wagner B, Laurent S, Krumbholz M, Breithaupt C, Högen T, Straube A, Giese A, Hohlfeld R, Lassmann H, Meinl E, Kümpfel T.

Ann Clin Transl Neurol. 2015 Mar;2(3):295-301. doi: 10.1002/acn3.164. Epub 2015 Jan 14.

50.

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.

Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G.

Neurology. 2015 Apr 14;84(15):1582-91. doi: 10.1212/WNL.0000000000001462. Epub 2015 Mar 20.

Supplemental Content

Loading ...
Support Center